Lonza CEO Pierre-Alain Ruffieux to Leave
Lonza CEO Pierre-Alain Ruffieux to Leave
Read moreDetailsLonza CEO Pierre-Alain Ruffieux to Leave
Read moreDetailsUpdated Sept. 9, 2023 10:51 am ETVivek Ramaswamy was a novice biotech entrepreneur in 2016 with no advanced medical training ...
Read moreDetailsText size Johnson & Johnson Benadryl brand allergy medication is now a part of Kenvue. Daniel Acker/Bloomberg Johnson & Johnson ...
Read moreDetailsText size Rivian Automotive saw its cash and cash equivalents decline by $6.6 billion last year. Patrick T. Fallon/AFP/Getty Images ...
Read moreDetailsResume Subscription We are delighted that you'd like to resume your subscription. You will be charged $ + tax (if ...
Read moreDetailsText size Johnson & Johnson took the Kenvue consumer-health business public in May. Mark Ralston/Getty Images Johnson and Johnson ’s ...
Read moreDetailsText size The Johnson & Johnson campus in Irvine, California. Mario Tama/Getty Images It’s crunchtime for investors in Johnson & ...
Read moreDetailsText size Cano posted a second-quarter net loss of $270.7 million. Stephen Zenner/Getty Images Cano Health stock was falling sharply ...
Read moreDetailsMany individual investors are trying to do that by purchasing 99 shares of Johnson & Johnson to take advantage of ...
Read moreDetailsText size Analysts project that Mounjaro will be the best-selling drug of all time. Dreamstime Sales of Eli Lilly ‘s ...
Read moreDetailsEmail Contact: souhaib@trendswide.com